Processa (PCSA) strategy chief buys 1,511 shares at $2.69

Rhea-AI Filing Summary

Processa Pharmaceuticals Chief Business-Strategy Officer Patrick Lin bought 1,511 shares of common stock in an open-market purchase at $2.69 per share. After this transaction, he directly owns 6,236 shares and indirectly holds 1,740 shares through the Lin Family Trust Feb 4, 2024.

Insider Trade Summary

Net Buyer: 1,511 shares ($4,065)

Net Buy 2 txns

Insider Lin Patrick

Role Chief Business - Strategy Off

Bought 1,511 shs ($4K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,511	$2.69	$4K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 6,236 shares (Direct, null); Common Stock — 1,740 shares (Indirect, Lin Family Trust Feb 4, 2024)

Footnotes (1)

Key Figures

Open-market purchase: 1,511 shares Purchase price: $2.69 per share Direct holdings after trade: 6,236 shares +2 more

5 metrics

Open-market purchase 1,511 shares Common Stock bought on 2026-04-30

Purchase price $2.69 per share Open-market purchase of common stock

Direct holdings after trade 6,236 shares Common Stock directly owned by Patrick Lin

Indirect holdings 1,740 shares Common Stock held via Lin Family Trust Feb 4, 2024

Net insider buying 1,511 shares Net buy direction in transaction summary

Key Terms

open-market purchase, indirect ownership, Lin Family Trust Feb 4, 2024, Form 4

4 terms

open-market purchase financial

"transaction_action: "open-market purchase" for 1,511 common shares at $2.6900"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"ownership_type: "indirect" for 1,740 common shares held via trust"

Lin Family Trust Feb 4, 2024 financial

"nature_of_ownership: "Lin Family Trust Feb 4, 2024" for 1,740 shares"

Form 4 regulatory

"INSIDER FILING DATA (Form 4): structured insider transaction report"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Patrick

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business - Strategy Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/30/2026		P		1,511	A	$2.69	6,236	D
Common Stock								1,740	I	Lin Family Trust Feb 4, 2024

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Processa Pharmaceuticals (PCSA) report for Patrick Lin?

Processa Pharmaceuticals reported that Chief Business-Strategy Officer Patrick Lin bought 1,511 shares of common stock. The shares were acquired in an open-market purchase at $2.69 per share, increasing his direct ownership stake in the company’s stock.

At what price did Patrick Lin buy Processa Pharmaceuticals (PCSA) shares?

Patrick Lin bought Processa Pharmaceuticals common stock at $2.69 per share. This price reflects an open-market purchase, meaning he acquired the shares on the public market rather than through a company grant or option exercise.

How many Processa Pharmaceuticals (PCSA) shares does Patrick Lin own after this filing?

After the reported transaction, Patrick Lin directly owns 6,236 Processa Pharmaceuticals shares. In addition, the filing shows 1,740 shares held indirectly through the Lin Family Trust dated February 4, 2024, reflecting both personal and trust-related holdings.

What type of ownership does the Lin Family Trust have in Processa Pharmaceuticals (PCSA)?

The Lin Family Trust Feb 4, 2024 holds 1,740 Processa Pharmaceuticals common shares as indirect ownership for Patrick Lin. Indirect ownership generally means the shares are controlled through a separate legal entity, such as a trust, rather than held personally.

Does the Processa Pharmaceuticals (PCSA) Form 4 show any insider share sales?

The Form 4 shows no insider share sales for Patrick Lin. It reports one open-market purchase of 1,511 common shares and an additional entry reflecting 1,740 shares held indirectly through the Lin Family Trust, without any disposition of shares.